Pending EU Approval Of Eloctate, Sobi Opts In To Second Hemophilia Program With Biogen
This article was originally published in The Pink Sheet Daily
Executive Summary
Sobi also gets two oral formulations of Orfadin for the rare genetic disorder HT-1 and is starting over with a new candidate in a collaboration with Affibody.